secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001193125-23-273563
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Q3 net revenues $102.7M (+79% YoY); non-GAAP EPS $0.49; raises FY revenue guidance to $390-395M
--------------------------------------------------------------------------------

- GAAP net loss per diluted share $(0.29) reflects $81.5M one-time IPR&D expense from AGAMREE license acquisition.
- Non-GAAP net income $55.9M ($0.49 diluted), up 95% YoY; total net revenues increased 79% to $102.6M.
- FDA approved AGAMREE (vamorolone) for Duchenne muscular dystrophy; commercial launch expected Q1 2024.
- Raised full-year 2023 total revenue guidance to $390-$395M from prior $370-$380M.
- sNDA for FIRDAPSE maximum daily dose increase to 100 mg accepted for filing by FDA; two new FIRDAPSE patents allowed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523273563/0001193125-23-273563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523273563/d581027d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-273563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer